Premium
Low‐density‐lipoprotein apheresis‐mediated endothelial activation therapy to severe‐peripheral artery disease study: Rationale and study design
Author(s) -
Ueda Eiko,
Toya Yoshiyuki,
Wakui Hiromichi,
Kawai Yuki,
Azushima Kengo,
Fujita Takayuki,
Saigusa Yusuke,
Yamanaka Takeharu,
Yabuki Yuichiro,
Mikami Taro,
Goda Motohiko,
Sugano Teruyasu,
Tamura Kouichi
Publication year - 2020
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.13546
Subject(s) - medicine , apheresis , peripheral , brachial artery , arterial disease , vascular disease , surgery , physical therapy , platelet , blood pressure
A novel approach is required for standard therapy‐resistant peripheral arterial disease (PAD). This is a single‐center, single‐arm, interventional study (LDL Apheresis‐Mediated Endothelial Activation Therapy to Severe‐Peripheral Artery Disease study), which aims to evaluate the efficacy and safety of lipoprotein apheresis (LA) with a dextran sulfate cellulose column in PAD with controlled serum cholesterol levels. The study participants have standard therapy‐resistant PAD with controlled serum cholesterol levels. A total of 35 patients undergo 10 sessions of LA therapy. The ankle‐brachial index and vascular quality of life questionnaire are assessed before and after the treatment period as primary outcomes. Registration of patients began in November 2015 and is planned to be concluded in October 2020.